Taysha releases interim data from REVEAL TSHA-102 trial
Taysha Gene Therapies have completed dosing of all 17 patients in the REVEAL trial of TSHA-102 gene therapy for Rett Syndrome.
Taysha also shared some very encouraging data from the REVEAL trial. All patients made improvements in their fine and gross motor skills and communication.
What does this mean?
REVEAL is the 3rd stage of Taysha’s gene therapy trial.
The trial tests TSHA-102 (the gene therapy treatment injected through the spine) on girls with Rett aged 6-21.
They have now finished dosing all patients in this stage of the trial and released data about 12 of them (those who have been on the trial for six months or more).
What does the interim data say?
TSHA-102 has been generally well-tolerated.
Any side effects were mild to moderate, with no serious effects reported as of the June 2026 data cut off.
All patients in the REVEAL Part A trial gained or regained more than one developmental milestone from the treatment.
Patients have made improvements in communication (speaking in phrases with meaning), fine motor skills (using utensils without assistance) and gross motor skills (walking without support).
Data suggests “broad functional impact consistently demonstrated across core disease domains (…) regardless of age, disease severity or genotype.”
And longer-term data shows a “durable and deepening treatment effect.”
Sean P. Nolan, Chairman and Chief Executive Officer of Taysha said the results: “continue to demonstrate the potential for TSHA-102 to transform the treatment paradigm for this devastating disease.”
Improvements were measured by multiple independent assessors who watched the patients on video.
What’s next?
Taysha will make an application to America’s Food and Drug Administration for a BLA, allowing TSHA-102 to be distributed in American markets.
They will complete this application by the end of the year and anticipate a response in the first half of next year.
Completion of dosing in the ASPIRE trial (another trial phase) is expected in July 2026
Our message to families
Whilst TSHA-102 is still in clinical trials, this is another positive step. It shows the programme is moving forward and that treatments are getting closer.
At Reverse Rett, we will keep:
Sharing updates in clear language
Supporting families to understand what’s happening
Pushing for faster, fairer access to treatments once they are proven to work